drugset
drugset / Trial / NCT02921919

Open-Label Extension and Safety Study of Talazoparib

NCT02921919 ↗

Phase 2 Completed 120 enrolled Pfizer Medivation, Inc. · collab
NaSingle-groupOpen-labelTreatment

Summary

This is a single-arm, open-label, extended treatment, safety study in patients treated with talazoparib in qualifying studies.

Timeline

Start
2016-11-08
Primary completion
2021-07-20
Completion
2021-07-20

Drugs

EvaluationDrugModalityDoseRoute
Subject Talazoparib Small molecule 1 mg —

Indications

cancer